What is on the table
Sanofi is studying an acquisition of Insmed, the respiratory disease specialist, with talks still in progress and any decision potentially weeks away, according to people who asked not to be named. They said there is no certainty a deal will happen and other bidders could appear.
Both companies declined to comment. If a transaction materializes, it would be the biggest biopharma deal since Pfizer bought Seagen for $43 billion in late 2023.
Insmed's rally reflected the chatter, while Sanofi slipped. Late morning in New York saw Insmed valued at $31.6 billion after the surge. Sanofi wrapped up trading in Paris off roughly 2.9%, with a valuation of about €101 billion.
Why Sanofi is shopping now
Big pharma is trying to refill pipelines with drugs that can replace aging blockbusters. Sanofi investors have been looking for a sizable purchase tied to a late stage program to help offset future sales lost when Dupixent's patent protection ends.
On last month's third quarter call, CEO Belén Garijo said mergers and acquisitions would be used as a growth lever. Garijo, who previously led Germany's Merck KGaA, took over earlier this year after Paul Hudson was ousted following an expensive R&D push that did not deliver as hoped.
When rumors swirl around deals, a clear, reliable take helps, so sign up for the free Market Briefs newsletter today
Sanofi has pointed to rare diseases as a focus and has signaled it may need to buy late stage and even commercial assets, which tend to be larger checks. Jefferies' Michael Leuchten wrote that while an Insmed deal "looks big on paper" for Sanofi, "it is doable, digestible and directionally seems consistent with what management was aiming for." The company's balance sheet has room, helped by last year's sale of a controlling stake in consumer health unit Opella to Clayton, Dubilier & Rice, which brought in roughly €10 billion of net cash. Chief Financial Officer François-Xavier Roger added, "The amount at stake is bigger than what we sought in the past."
What Insmed would add
Bridgewater, New Jersey-based Insmed sells two approved respiratory drugs. Brinsupri treats non-cystic fibrosis bronchiectasis, and Arikayce is indicated for lung disease caused by refractory mycobacterium avium complex. The company raised its 2026 revenue guidance at the bottom end for these products last month, and reported third quarter revenue up 268% year over year to $524.4 million.
"The strategic fit is clear for both companies and represents an opportunity for Sanofi to leverage their existing commercial infrastructure to aid in Insmed's launch of Brinsupri," BMO Capital Markets analysts Conor MacKay and Evan David Seigerman wrote Thursday. Insmed is also developing earlier-stage programs in respiratory disease, as well as in immunology, inflammation and neurological areas, and, recently, it named Hudson to its board as an independent member.
What changes under Garijo and what to watch
Beyond shutting down several projects judged unlikely to succeed, Garijo removed R&D chief Houman Ashrafian and installed Paulo Fontoura, a former Roche executive, in the position. Management is targeting faster development, with plans to initiate as many as 15 first-in-human trials annually. Some trials have underwhelmed, among them those for the atopic dermatitis prospect amlitelimab and for a therapy targeting a rare autoimmune disease, and the company plans to present an update on strategic priorities by year end.
The bottom line: Insmed's jump prices in deal hopes, but negotiations could take weeks and might not yield a transaction. For portfolios exposed to Sanofi or Insmed, you are watching a classic event setup with a buyer signaling larger M&A and a target growing respiratory sales that fit those priorities.
Because quick headlines can be noisy, get a five-minute rundown every morning with the free Market Briefs
